checkAd

     133  0 Kommentare INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro Under Compassionate Use for Over Three Years - Seite 2

    A video with a patient sharing their experience in the Phase I clinical trial, the open-label extension trial, and the Australian SAS can be found by clicking here. Additionally, the principal investigator who treated both patients previously commented on their response to XProTM as part of a webinar given by the Company describing the results of the AD01 Phase 1b trial in 2022 by clicking here (at 6:50 min mark).  

    “We are delighted to report that according to primary care physicians treating these patients under the SAS, the long-term administration of XPro has been safe and well-tolerated with these patients maintaining stable cognitive functions for more than three years of continued XPro treatment," expressed R.J. Tesi, M.D., CEO of INmune Bio. "Given the typical progression of Alzheimer's Disease and comparative data from other drug trials, stable cognitive and physical function over this long period is encouraging.” 

    The Company remains on track in alignment with prior guidance for completing the current Phase 2 clinical trial investigating XProTM for treatment of AD in patients with biomarkers of inflammation.

    About INmune Bio, Inc.

    Lesen Sie auch

    INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are being investigated to determine if they can treat cancer (INB03), Early Alzheimer’s disease, and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.

    Seite 2 von 4



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro Under Compassionate Use for Over Three Years - Seite 2 Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -  INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is …